Corporate Board Profile
Tech Score: 50/100
1 mention(s) identify DAVID F. WELCH, PH.D. as having software/technology expertise.
| Company | Filing Date | Evidence | Reason |
|---|---|---|---|
| CytoDyn Inc. | 2019-08-21 | Dr. Welch was named the Chief Innovation Officer of Infinera Corporation, a company which he co-founded. He served as Chief Strategy and Technology Officer, President, Executive Vice President and Chief Strategy Officer, and Chief Development Officer/CTO. He holds a B.S. in Electrical Engineering from the University of Delaware and a Ph.D. in Electrical Engineering from Cornell University. Dr. Welch holds over 130 patents and has been awarded multiple technical awards. | Dr. Welch has extensive technical and engineering experience including serving as Chief Technology Officer and Chief Development Officer at technology companies, holds a Ph.D. in Electrical Engineering, and holds over 130 patents, indicating strong software and technical skills. |
| Filing Date | Source Excerpt |
|---|---|
| 2019-08-21 | Dr. Welch was named the Chief Innovation Officer of Infinera Corporation, a company which he co-founded. He served as Chief Strategy and Technology Officer, President, Executive Vice President and Chief Strategy Officer, and Chief Development Officer/CTO. He holds a B.S. in Electrical Engineering from the University of Delaware and a Ph.D. in Electrical Engineering from Cornell University. Dr. Welch holds over 130 patents and has been awarded multiple technical awards. |
| 2020-06-22 | David F. Welch, Ph.D. (4) Includes: (i) 9,513,417 shares of Common Stock, 1,000 shares of Series D Convertible Preferred Stock convertible into 1,250,000 shares of Common Stock and a warrant covering 500,000 shares of Common Stock held by a limited liability company for which Dr. Welch is the managing member and has voting and dispositive power; (ii) 3,002,202 shares of Common Stock held directly by a trust for which Dr. Welch, as trustee, has voting and dispositive power; and (iii) 1,295,154 shares of Common Stock subject to options held directly by Dr. Welch. |
Data sourced from SEC filings. Last updated: 2026-02-03